BACKGROUND: We conducted a study exploring the clinical safety and efficacy of @entity11508 in @entity1 with @entity3052 ( @entity3052 ) and @entity2590 ( @entity2590 ), combined with a complex karyotype. MATERIALS AND METHODS: From April 2009 to September 2013, a total of 35 @entity1 with @entity3052 / @entity2590 combined with a complex karyotype diagnosed in the First Affiliated Hospital of Soochow University were included for retrospective analysis. All @entity1 were treated with @entity11508 alone (20mg/m2 daily for 5 days) or combination AAG chemotherapy (Acla 20mg qod*4d, @entity2592 10mg/m2 q12h*7d, @entity1261 300 g qd, the dose of @entity1261 adjusted to the amount in blood routinely). RESULTS: In 35 @entity1 , 15 exhibited a complete response (CR), and 6 a partial response (PR), the overall response rate (CR+PR) being 60% (21 of 35). Median disease-free survival was 18 months and overall survival was 14 months. In the 15 @entity2590 @entity1 with a complex karyotype, the CR rate was 53.3% (8 of 15); in 20 @entity3052 @entity1 with complex karyotype, the overall response rate was 65% (13 of 20). The response rate of @entity11508 alone (22 cases) was 56.5% (13 of 22), while in the combination chemotherapy group (13 cases), the effective rate was 61.5% (8 of 13)(P>0.05). There are 15 @entity1 with chromosome 7 aberration, after treatment with @entity11508 , 7 CR, 3 PR, overall response rate was 66.7% (10 of 15). Of 18 @entity1 with 3 to 5 kinds of @entity2008 , 66.7% demonstrated a response; of 17 with more than 5 @entity2008 , 52.9% had a response. In the total of 35 @entity1 , with one course (23 @entity1 ) and >= two courses (12 @entity1 ), the overall response rate was 40.9% and 92.3% (P<0.05). Grade III to IV hematological @entity137 was observed in 27 cases (75%). Grade III to IV @entity281 were clinically documented in 7 (20%). Grades I to II non-hematological @entity137 were @entity281 (18 @entity1 ), haematuria (2 @entity1 ), and @entity548 (3 @entity1 ). With follow-up until September 2013, 7 @entity1 were surviving, 18 had died and 10 were lost to follow-up. In the 6 cases who underwent allogeneic hematopoietic stem cell transplantation (HSCT) all were still relapse-free survivors. CONCLUSIONS: @entity11508 alone or combination with AAG can improve outcome of @entity3052 / @entity2590 with a complex karyotype, there being no significant difference @entity11508 in inducing remission rates in @entity1 with different karyotype. Increasing the number of courses can improve efficiency. This approach with fewer @entity458 in @entity1 with a better tolerance should be employed in order to create an improved subsequent chance for HSCT.

XXXX in the Treatment of @entity3052 and @entity2590 Syndromes, Which Combined with Complex Karyotype Respectively.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndromes', 'MDS'] @entity458 :: ('MESH:D020018', 'Disease') :: ['treatment side effects'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['Ara-C'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections'] @entity2008 :: ('MESH:D002869', 'Disease') :: ['chromosomal abnormalities'] @entity11508 :: ('MESH:C014347', 'Chemical') :: ['Decitabine', 'decitabine']
@entity11508 :: (MESH:C014347,Chemical) :: ['Decitabine']
